Renfeng Guo, MD

Chief Scientific Officer
InflaRx Pharmaceuticals, Inc.

Poster(s):

• (645) Vilobelimab With Baseline Vasopressor Use Improves Mortality in Critically Ill COVID-19 Patients
  Sunday, February 23, 2025

  2:30pm – 3:30pm Eastern Time